

Sheryl A Zelenitsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8086656/publications.pdf>

Version: 2024-02-01

78
papers

4,470
citations

182225

30
h-index

120465

65
g-index

81
all docs

81
docs citations

81
times ranked

4518
citing authors

#	ARTICLE	IF	CITATIONS
1	An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	0.5	2
2	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> , 2022, 82, 533-557.	4.9	12
3	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2021, 81, 233-256.	4.9	20
4	Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia or Pneumonia. <i>Canadian Journal of Hospital Pharmacy</i> , 2021, 74, 334-343.	0.1	1
5	Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 327-334.	1.6	13
6	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. <i>Drugs</i> , 2020, 80, 285-313.	4.9	60
7	Clinical Blood Isolates from Hemodialysis Patients: Distribution of Organisms and Antimicrobial Resistance, 2007-2014. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, 266-271.	0.1	0
8	Clinical Blood Isolates from Hemodialysis Patients: Distribution of Organisms and Antimicrobial Resistance, 2007-2014. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, .	0.1	0
9	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019, 79, 271-289.	4.9	274
10	Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1888-1894.	1.3	18
11	Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 768-771.	1.3	14
12	Imipenem-Relbactam and Meropenem-Vaborbactam: Two Novel Carbapenem- β -Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.	4.9	291
13	Antimicrobial Prophylaxis for Patients Undergoing Cardiac Surgery: Intraoperative Cefazolin Concentrations and Sternal Wound Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	19
14	Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass- ⁹ authors TM response. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2588-2588.	1.3	0
15	Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Annals of Pharmacotherapy</i> , 2018, 52, 965-973.	0.9	14
16	No role for patient body weight on renal function assessment for drug dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1802-1811.	1.3	3
17	Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. <i>Peritoneal Dialysis International</i> , 2017, 37, 170-176.	1.1	35
18	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016, 76, 1737-1757.	4.9	38

#	ARTICLE	IF	CITATIONS
19	Targeted benefits of prolonged-infusion piperacillin-tazobactam in an <i>in vitro</i> infection model of <i>Pseudomonas aeruginosa</i> . <i>Journal of Chemotherapy</i> , 2016, 28, 390-394.	0.7	15
20	Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2902-2908.	1.3	12
21	Multifaceted antibiotic treatment analysis of methicillin-sensitive <i>Staphylococcus aureus</i> bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 674-679.	1.1	7
22	Pharmacodynamics of Antimicrobial Prophylaxis in Cardiac Surgery: Association Between Intraoperative Cefazolin Concentrations and Postoperative Infections. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
23	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.	4.9	199
24	Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. <i>Drugs</i> , 2015, 75, 253-270.	4.9	140
25	Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. <i>Clinical Pharmacokinetics</i> , 2015, 54, 783-795.	1.6	107
26	Using Curriculum Mapping to Engage Faculty Members in the Analysis of a Pharmacy Program. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 139.	0.7	24
27	Ceftolozane/Tazobactam: A Novel Cephalosporin/ β -Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2014, 74, 31-51.	4.9	279
28	Vancomycin pharmacodynamics and survival in patients with methicillin-resistant <i>Staphylococcus aureus</i> -associated septic shock. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 255-260.	1.1	99
29	Ceftazidime-Avibactam: a Novel Cephalosporin/ β -lactamase Inhibitor Combination. <i>Drugs</i> , 2013, 73, 159-177.	4.9	362
30	Successful Treatment of Pulmonary Blastomycosis with Continuously Infused Amphotericin B Deoxycholate After Failure with Liposomal Amphotericin B. <i>Annals of Pharmacotherapy</i> , 2013, 47, e26-e26.	0.9	9
31	Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of <i>Pseudomonas aeruginosa</i> causing infections in Canadian hospitals (CANWARD). <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i67-i72.	1.3	21
32	Treatment Strategies for Recurrent <i>Clostridium difficile</i> Infection. <i>Canadian Journal of Hospital Pharmacy</i> , 2013, 66, 361-8.	0.1	21
33	Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis. <i>Clinical Infectious Diseases</i> , 2012, 55, 527-533.	2.9	30
34	Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 459-473.	2.0	171
35	Pharmacodynamic Profiling of Antimicrobials against Gram-negative Respiratory Isolates from Canadian Hospitals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, 132-136.	0.7	6
36	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011, 37, 632-638.	3.9	90

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 343-349.	1.3	47
38	Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant <i>Staphylococcus aureus</i> , heteroresistant vancomycin-intermediate <i>S. aureus</i> , vancomycin-intermediate <i>S. aureus</i> and vancomycin-resistant <i>S. aureus</i> using an in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1301-1305.	1.3	24
39	Preferential Emergence of Reduced Vancomycin Susceptibility in Health Care-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates during Continuous-Infusion Vancomycin Therapy in an <i>In Vitro</i> Dynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3627-3630.	1.4	11
40	Evaluation of the Research Grant Program of the Foundation of the Canadian Society of Hospital Pharmacists, 1995-2008. <i>Canadian Journal of Hospital Pharmacy</i> , 2011, 64, 399-404.	0.1	4
41	Should IV Antibiotics Be Administered by Prolonged Infusion?. <i>Canadian Journal of Hospital Pharmacy</i> , 2010, 63, 246-9.	0.1	2
42	Support for higher ciprofloxacin AUC ₂₄ /MIC targets in treating Enterobacteriaceae bloodstream infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1725-1732.	1.3	69
43	Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. <i>Cmaj</i> , 2010, 182, 357-363.	0.9	99
44	New Lipoglycopeptides. <i>Drugs</i> , 2010, 70, 859-886.	4.9	280
45	Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1476-1481.	1.4	114
46	Simulation of cyclic reprocessing buildup on reused medical devices. <i>Computers in Biology and Medicine</i> , 2009, 39, 568-577.	3.9	10
47	Ceftaroline. <i>Drugs</i> , 2009, 69, 809-831.	4.9	114
48	Effect of an ethanol/trisodium citrate hemodialysis catheter locking solution on isolates of <i>Candida albicans</i> . <i>Hemodialysis International</i> , 2008, 12, 342-347.	0.4	7
49	Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1024-1026.	1.3	34
50	Aminoglycoside-Induced Vestibular Injury: Maintaining a Sense of Balance. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1282-1289.	0.9	72
51	Effect of Ethanol/Trisodium Citrate Lock on Microorganisms Causing Hemodialysis Catheter-Related Infections. <i>Journal of Vascular Access</i> , 2007, 8, 262-267.	0.5	15
52	An Evaluation of an Optimal Sampling Strategy for Meropenem in Febrile Neutropenics. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 832-835.	1.0	7
53	Adequacy of a Vancomycin Dosing Regimen in Patients Receiving High-Flux Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2005, 46, 681-687.	2.1	58
54	Evaluating Ciprofloxacin Dosing for <i>Pseudomonas aeruginosa</i> Infection by Using Clinical Outcome-Based Monte Carlo Simulations. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4009-4014.	1.4	40

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia. <i>Annals of Pharmacotherapy</i> , 2005, 39, 32-38.	0.9	168
56	Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of <i>Stenotrophomonas maltophilia</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 39-43.	0.8	69
57	Peritoneal Fluid Titer Test for Peritoneal Dialysis-Related Peritonitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1719-1726.	1.4	5
58	A reevaluation of empiric therapy for peritoneal dialysis-related peritonitis. <i>American Journal of Kidney Diseases</i> , 2004, 44, 559-561.	2.1	4
59	Effect of antibiotic sequence on combination regimens against <i>Pseudomonas aeruginosa</i> in a multiple-dose, in vitro infection model. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 67-70.	0.8	5
60	Bayesian Pharmacokinetic Analysis of a Gentamicin Nomogram in Neonates: A Retrospective Study. <i>Current Therapeutic Research</i> , 2003, 64, 178-188.	0.5	4
61	Treatment and outcome of <i>Pseudomonas aeruginosa</i> bacteraemia: an antibiotic pharmacodynamic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 668-674.	1.3	130
62	AUC _{0-t} /MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for <i>Streptococcus pneumoniae</i> in an in vitro infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 905-911.	1.3	19
63	Antibiotic Pharmacodynamics in Surgical Prophylaxis: an Association between Intraoperative Antibiotic Concentrations and Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3026-3030.	1.4	124
64	An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 693-696.	1.3	25
65	Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 863-866.	1.3	13
66	Challenging the Current Treatment Paradigm for Methicillin-Resistant <i>Staphylococcus Epidermidis</i> Peritonitis in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 335-338.	1.1	26
67	Challenging the current treatment paradigm for methicillin-resistant <i>Staphylococcus epidermidis</i> peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 335-8.	1.1	7
68	A prospective, randomized, double-blind study of single high dose versus multiple standard dose gentamicin both in combination with metronidazole for colorectal surgical prophylaxis. <i>Journal of Hospital Infection</i> , 2000, 46, 135-140.	1.4	40
69	Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. <i>American Journal of Kidney Diseases</i> , 2000, 36, 1009-1013.	2.1	166
70	Synergy of an Investigational Glycopeptide, LY333328, with Once-Daily Gentamicin against Vancomycin-Resistant <i>Enterococcus faecium</i> in a Multiple-Dose, In Vitro Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 592-597.	1.4	22
71	Once versus Thrice Daily Tobramycin Alone and in Combination with Ceftazidime, Ciprofloxacin and Imipenem in an in vitro Pharmacodynamic Model. <i>Chemotherapy</i> , 1998, 44, 1-6.	0.8	5
72	Susceptibilities of <i>Candida</i> Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2446-2448.	1.4	16

#	ARTICLE	IF	CITATIONS
73	Altered denA and anr gene expression in aminoglycoside adaptive resistance in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 371-376.	1.3	23
74	In vitro antifungal activity of BMS-181184 against systemic isolates of <i>Candida</i> , <i>Cryptococcus</i> , and <i>Blastomyces</i> species. <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 28, 179-182.	0.8	5
75	In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of <i>Candida</i> species, <i>Cryptococcus neoformans</i> , <i>Blastomyces dermatitidis</i> , and <i>Aspergillus</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 863-865.	1.4	104
76	Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant <i>Enterococcus faecium</i> strains. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 1407-1408.	1.4	26
77	In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant <i>Candida</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2576-2578.	1.4	28
78	Phenazopyridine in Urinary Tract Infections. <i>Annals of Pharmacotherapy</i> , 1996, 30, 866-868.	0.9	18